GO
Loading...

Eli Lilly and Co

More

  • March 12- The number of U.S. cattle deaths that may be linked to the Merck& Co Inc feed additive Zilmax are much higher than the figures reported by the drug company to the federal government, according to a research study published on Wednesday.

  • Midday movers: Facebook, Target, PetSmart & More Wednesday, 5 Mar 2014 | 11:41 AM ET

    Some of Wednesday's midday movers:

  • Midday movers: EBay, Pfizer, Dillard's & More Monday, 24 Feb 2014 | 12:53 PM ET

    Some of Monday's midday movers:

  • Midday Movers: FB, CHK, DVN & more Wednesday, 19 Feb 2014 | 12:14 PM ET
    Facebook's Paper mobile app

    Take a look at some of Wednesday's midday movers:

  • Feb 19- An experimental cancer drug developed by Eli Lilly and Co, touted by some to be the company's next blockbuster, significantly improved survival rates in lung cancer patients, sending the company's shares up 3 percent in early trading.

  • Feb 19- Eli Lilly and Co said its experimental lung cancer drug significantly improved patient survival rates compared to a placebo in a late-stage trial. The trial also showed that the drug, ramucirumab, improved survival rates without the cancer worsening. Lilly shares rose 3 percent to $57 in premarket trade on Wednesday.

  • Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.

  • *More drugmakers could opt not to launch drugs in Germany. FRANKFURT/ BERLIN, Feb 18- Germany's plan to publish price discounts agreed with drugmakers poses a risk to profits in the industry, which fears the information could be used to drive down prices elsewhere.

  • PARIS, Feb 6- French drugmaker Sanofi's forecast for a return to profit growth after three years of decline failed to impress investors on Thursday, sending its shares to a one-year low.

  • *Pfizer to discuss favorable data with FDA. Feb 3- Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

  • Feb 3- Pfizer Inc's experimental breast cancer drug significantly improved patient survival rates in a mid-stage trial without their condition worsening, maintaining the company's lead in the race for a new treatment standard for the disease.

  • Early movers: GOOG, TYC, YHOO & more Friday, 31 Jan 2014 | 7:49 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • *Sanofi alleges Lilly infringed four patents. *Sanofi, Novo shares rise on delayed biosimilar threat. NEW YORK/ PARIS, Jan 31- French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. firm's plans to produce a copycat version of Lantus.

  • Jan 30- French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus.

  • Treasurys trim losses after 5, 7-year debt auction Thursday, 30 Jan 2014 | 4:35 PM ET

    Treasurys held on to earlier losses after of the Treasury Dept's auction of five-year notes and seven-year debt and after the release of US GDP data.

  • US stock-index futures higher after GDP, jobless claims Thursday, 30 Jan 2014 | 8:50 AM ET

    U.S. stock index futures traded higher on Thursday, on what will be the busiest day of fourth quarter earnings season.

  • Early movers: MMM, UPS, V, GOOG & more Thursday, 30 Jan 2014 | 7:47 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Lilly quarterly sales soundly beat forecasts Thursday, 30 Jan 2014 | 7:23 AM ET

    Eli Lilly reported sales well above Street expectations, although overall revenue declined due to generic competition for Cymbalta.

  • Eli Lilly CEO: 2014 is inflection year for us     Thursday, 30 Jan 2014 | 7:17 AM ET

    Eli Lilly Chairman & CEO John Lechleiter discusses the productivity in its labs to find new medicines, and how the Affordable Care Act is impacting his business.

  • Lilly quarterly sales soundly beat forecasts Thursday, 30 Jan 2014 | 6:45 AM ET

    Jan 30- Eli Lilly and Co reported quarterly revenue well above Wall Street expectations, although overall revenue declined due to generic competition for the company's Cymbalta depression treatment. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring.

Most Popular Video

Thursday, 17 Apr 2014 | 1:03 PM ET

Dissecting the current market action amid geopolitical concerns, with Kenny Polcari, O'Neil Securities, and CNBC's Dominic Chu.

Thursday, 17 Apr 2014 | 12:06 PM ET

Discussing the case for stocks, with Ed Yardeni, president and chief investment strategist of Yardeni Research. He thinks the market had an "internal correction."

Thursday, 17 Apr 2014 | 1:00 PM ET

Secretary of State John Kerry comments after a meeting in Geneva with Russian Foreign Minister Sergey Lavrov and representatives of the EU and Ukraine.